Glenmark Pharmaceuticals Limited – Q1 FY26 Results Summary
Announcement Date: 14 August 2025

Key Financial Metrics (Standalone):

  • Revenue from operations: ₹23,949 million, up 18.8% QoQ (₹20,095 million in Q4 FY25), down 2.9% YoY (₹23,295 million in Q1 FY25)
  • Profit before exceptional items & tax: ₹7,244 million (29.4% margin), up from ₹3,603 million (17.2%) QoQ
  • Exceptional items: ₹3,232 million provision related to US antitrust litigation settlements
  • Profit after tax: ₹3,302 million (13.4% margin), up from ₹1,478 million QoQ, down from ₹4,537 million YoY
  • EPS (Basic & Diluted): ₹11.70, up from ₹5.24 QoQ, down from ₹16.08 YoY

Key Financial Metrics (Consolidated):

  • Revenue from operations: ₹32,644 million, flat QoQ and YoY
  • Profit before exceptional items & tax: ₹4,188 million, up from ₹3,808 million QoQ, down from ₹4,623 million YoY
  • Exceptional items: ₹3,232 million provision for US litigation settlements
  • Profit after tax: ₹470 million, up from ₹44 million QoQ, down from ₹3,402 million YoY
  • EPS (Basic & Diluted): ₹1.66, up from ₹0.16 QoQ, down from ₹12.06 YoY

Balance Sheet / Other Items:

  • No material changes or disclosures on debt, cash reserves, or capital assets in this filing.
  • Employee stock options outstanding: 131,881 as of 30 June 2025.

Management Commentary:

  • Results prepared under Ind AS and reviewed by audit committee; clean auditor’s limited review report with no qualifications.
  • Exceptional provision relates to settlement of multiple US antitrust and consumer protection lawsuits; settlement subject to court approval, with no admission of liability.
  • Restructuring of innovation arm IGI Therapeutics SA ongoing, involving project closures and facility shutdowns, incurring restructuring costs in FY25.
  • No changes in accounting policies or material adjustments reported.

Segment Performance:

  • Company operates in a single segment: Pharmaceuticals (generics and active pharmaceutical ingredients).
  • No further segment or geographic revenue breakdown provided.

Key Developments:

  • Provision for US antitrust litigation settlements of ₹3.23 billion in Q1 FY26.
  • IGI Therapeutics restructuring continues with associated costs recognized in prior year.
  • No new capex, acquisitions, disposals, or mergers disclosed.

Outlook:

  • No explicit guidance or outlook provided in this announcement.

Please advise if further detailed analysis on subsidiaries or specific financial line items is required.